MediPoint: Total Hip Replacement - EU Analysis and Market Forecasts

Reportbuyer.com just published a new market research report: MediPoint: Total Hip Replacement - EU Analysis and Market Forecasts

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friendRepost This

London (PRWEB) November 05, 2013

Summary

Osteoarthritis has become a global public health concern with no cure. It is the most common form of arthritis that is primarily due to wear and tear of the joints. With the aging global population, this is an indication that is growing rapidly with the hip being one of the most common joints afflicted. While the primary indication for total hip replacement (THR) is osteoporosis, the other major indications for THR are osteonecrosis and fractures to a lesser degree. As people live longer and with younger patients also receiving implants, the revision rates for primary hip replacements are also expected to rise. Primary hip replacement has become one of the most successful surgeries, with a variety of femoral and acetabular components available from a wide selection of manufacturers. This report focuses on the total primary hip replacement market along with primary revision market. The global hip replacement market has been estimated in this report which includes France, Germany, Italy, Spain, UK. The report provides unmet needs, future adoption and compounded annual growth rates (CAGR). GlobalData’s analysis shows that the hip replacement market has become a mature market where products have become commodities. The future of the market lays on the ability of manufacturers to provide implants at a very low cost while continuing to provide the same level of clinical efficacy. The product development need lies primarily in revising the resurfacing products’ articulating surface with new materials rather than developing new acetabular and femoral components. Additionally the major opportunity lies within the emerging markets which are the countries that have a higher CAGR and will provide the key for growth and grabbing market share.

Scope

-An overview of Osteoarthritis, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
-Annualized EU THR market revenue and future forecasts from 2009 to 2011, forecast for 7 years to 2018.
-Investigation of current and future market competition for THR
-Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
-Competitor assessment including device approval analysis and device sales forecasts.
-Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
-Analysis of unmet needs within the market and opportunities for future players.
-Technology trends evaluation to assess strength of pipeline.
-An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
-Company profiles including business description, financial overview and SWOT analysis.
-Coverage of key market players.
-Strategic assessment of the THR sector through market impact analysis, future market scenario and company analysis.
-Direct quotes from Key Opinion Leaders (KOL) as well as Orthopedic Surgeon.

Reasons to buy

-Understand the trends shaping and driving the EU THR Market.
-Realize device preferences of physicians who have performed the tests already.
-Access market sizing, forecasts and quantified growth opportunities in the EU THR market through 2018.
-Quantify candidate patient populations to better design product pricing & launch plans.
-Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
-Perform benchmarking analysis of growth opportunities against currently marketed products.
-Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
-Take a comprehensive look at the market’s device pipeline and identify promising, paradigm-shifting products.
-Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
-Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.
-What’s the next big thing in EU THR market landscape? Identify, understand and capitalize.

1 Table of Contents
1 Table of Contents 7
1.1 List of Tables 16
1.2 List of Figures 26
2 Introduction 30
2.1 Catalyst 31
3 Disease Overview 32
3.1 Anatomy and Physiology 32
3.2 Pathophysiology 33
3.2.1 Overview 33
3.2.2 Osteoarthritis 34
3.2.3 Rheumatoid Arthritis 34
3.2.4 Post-traumatic Arthritis 35
3.2.5 Osteonecrosis 35
3.2.6 Injury 36
3.2.7 Bone Tumors 36
3.2.8 Other Diseases 36
3.3 Clinical Presentation 37
3.4 Clinical Outcomes 38
3.4.1 Overview 38
3.4.2 Conservative Therapy 41
3.4.3 Hip Arthroscopy 41
3.4.4 Hip Arthrodesis 42
3.4.5 Hemiarthroplasty (Partial) 43
3.4.6 Core Decompression 43
3.4.7 Hip Osteotomy 44
3.4.8 Resection Arthroplasty 44
3.4.9 Primary Total Hip Replacement 45
3.4.10 Revision Total Hip Replacement 47
3.4.11 Resurfacing Arthroplasty 48
3.4.12 Computer-Navigated Hip Replacement 49
3.5 Surgical Approaches 49
3.5.1 Anterolateral Approach 50
3.5.2 Posterior Approach 51
3.5.3 Direct Anterior Approach 52
3.5.4 Minimally Invasive Approaches 53
3.6 Epidemiology 54
3.6.1 EU 56
3.7 Economic Impact 58
3.7.1 EU 59
4 Competitive Assessment 61
4.1 Overview of Historical Designs 61
4.2 Marketed Products 62
4.2.1 Global Market Share 62
4.2.2 Primary Total Hip Replacement 64
4.2.3 Product Profiles by Company 65
5 Unmet Needs 219
5.1 Long-Term Clinical Data 219
5.2 Need for Continued Materials Research 220
5.3 Bearings 222
5.4 Refocus of Pipeline Products 223
5.5 Renewal of Resurfacing 224
5.6 Addressing the Learning Curve for Tier II Surgeons 226
5.7 Need for Cost Containment 228
5.8 Centralization 229
5.9 National Joint Registry 230
6 Pipeline Products 231
6.1 Overview 231
6.2 Primary Total Hip Pipeline Products 232
6.2.1 Exactech LPI Prime Hip System 232
6.2.2 EnduRo Bone-preserving Hip Stem 233
6.2.3 Deltamotion Acetabular Cup System 233
6.2.4 NovoSource Hip Implant 233
7 Industry Overview 234
7.1 Procedure Volumes 234
7.1.1 EU 235
7.2 Market Access 237
7.2.1 EU 238
7.3 Reimbursement Trends 240
7.3.1 Europe 240
7.4 Regulatory Issues/Recalls 245
7.4.1 DePuy Hip Replacement Recall 245
7.4.2 Stryker Hip Replacement Recall 246
7.4.3 Smith & Nephew Recall: R3 Metal Liners of the R3 Acetabular System 246
7.4.4 Zimmer Durom® Acetabular Component 246
7.4.5 Biomet Hip Replacement Complications 246
7.4.6 Wright Medical Conserve Hip Implant 247
7.4.7 The Corin Group Metal-on-Metal Hip Resurfacing 247
7.5 Mergers & Acquisitions / Key Partnerships 248
7.5.1 Medtronic Acquires China Kanghui Holdings 248
7.5.2 Tornier Acquires OrthoHelix Surgical Designs Inc. 248
7.5.3 DePuy Orthopaedics (Johnson & Johnson) and Synthes Inc. Merge 248
7.5.4 Italian Consortium 2IL Orthopaedics Ltd Acquires Corin Group 249
7.5.5 Zimmer Acquires Beijing Montagne Medical Device Co. Ltd. 249
7.5.6 Wright Medial Announces Agreement to Sell OrthoRecon Business to MicroPort Medical B.V. 249
8 Company Profiles 250
8.1 B. Braun 250
8.1.1 Overview 250
8.1.2 Portfolio Assessment 251
8.1.3 SWOT Analysis 251
8.2 Biomet Orthopedics 252
8.2.1 Overview 252
8.2.2 Portfolio Assessment 253
8.2.3 SWOT Analysis 256
8.3 Corentec Co. Ltd. 257
8.3.1 Overview 257
8.3.2 Portfolio Assessment 257
8.3.3 SWOT Analysis 258
8.4 Corin 258
8.4.1 Overview 258
8.4.2 Portfolio Assessment 259
8.4.3 SWOT Analysis 260
8.5 DePuy Synthes International 261
8.5.1 Overview 261
8.5.2 Portfolio Assessment 262
8.5.3 SWOT Analysis 265
8.6 Exactech 265
8.6.1 Overview 265
8.6.2 Portfolio Assessment 266
8.6.3 SWOT Analysis 268
8.7 Iconacy Orthopedic Implants LLC 269
8.7.1 Overview 269
8.7.2 Portfolio Assessment 269
8.7.3 SWOT Analysis 270
8.8 Implantcast GMBH 271
8.8.1 Overview 271
8.8.2 Portfolio Assessment 271
8.8.3 SWOT Analysis 273
8.9 JRI Orthopaedics 274
8.9.1 Overview 274
8.9.2 Portfolio Assessment 275
8.9.3 SWOT Analysis 276
8.10 Kyocera 277
8.10.1 Overview 277
8.10.2 Portfolio Assessment 278
8.10.3 SWOT Analysis 279
8.11 Limacorporate S.P.A 280
8.11.1 Overview 280
8.11.2 Portfolio Assessment 281
8.11.3 SWOT Analysis 282
8.12 Medacta 283
8.12.1 Overview 283
8.12.2 Portfolio Assessment 284
8.12.3 SWOT Analysis 285
8.13 Medtronic 285
8.13.1 Overview 285
8.13.2 Portfolio Assessment 286
8.13.3 SWOT Analysis 287
8.14 NovoSource Inc. 288
8.14.1 Overview 288
8.14.2 Portfolio Assessment 288
8.14.3 SWOT Analysis 289
8.15 Peter Brehm GMBH 289
8.15.1 Overview 289
8.15.2 Portfolio Assessment 290
8.15.3 SWOT Analysis 290
8.16 Serf Dedienne Santé 291
8.16.1 Overview 291
8.16.2 Portfolio Assessment 292
8.16.3 SWOT Analysis 293
8.17 Smith & Nephew 293
8.17.1 Overview 293
8.17.2 Portfolio Assessment 294
8.17.3 SWOT Analysis 296
8.18 Stelkast 297
8.18.1 Overview 297
8.18.2 Portfolio Assessment 298
8.18.3 SWOT Analysis 298
8.19 Stryker 299
8.19.1 Overview 299
8.19.2 Portfolio Assessment 301
8.19.3 SWOT Analysis 302
8.20 Tianjin Zhengtian Medical Instrument Co., Ltd. 303
8.20.1 Overview 303
8.20.2 Portfolio Assessment 303
8.20.3 SWOT Analysis 304
8.21 Tornier N.V. 305
8.21.1 Overview 305
8.21.2 Portfolio Assessment 306
8.21.3 SWOT Analysis 308
8.22 Wright Medical 309
8.22.1 Overview 309
8.22.2 Portfolio Assessment 310
8.22.3 SWOT Analysis 312
8.23 United Orthopedic Corporation 313
8.23.1 Overview 313
8.23.2 Portfolio Assessment 314
8.23.3 SWOT Analysis 314
8.24 Zimmer Holdings Inc. 315
8.24.1 Overview 315
8.24.2 Portfolio Assessment 317
8.24.3 SWOT Analysis 318
8.25 Other Companies 319
9 Market Drivers, Opportunities and Barriers 320
9.1 Market Drivers 320
9.1.1 Prevalence Rise 320
9.1.2 Expanding Indications 322
9.1.3 Availability and Lack of Long-Term Clinical Data 323
9.1.4 Fracture Incidence 323
9.1.5 Patient Demand and Awareness 323
9.2 Opportunities 324
9.2.1 Revision Surgery 324
9.2.2 Emerging Markets 325
9.2.3 Continued Materials Research 326
9.2.4 Corporate Promotions and Teaching Seminars 326
9.2.5 Advancement towards Cost Reduction 327
9.3 Market Barriers 328
9.3.1 Market Barriers 328
10 Country Outlooks & Forecasts 332
10.1 EU Markets Overview 332
10.2 France Market Analysis 336
10.3 Germany Market Analysis 338
10.4 Italy Market Analysis 340
10.5 Spain Market Analysis 341
10.6 UK Market Analysis 343
11 Appendix 345
11.1 Abbreviations 345
11.2 Bibliography 347
11.3 Report Methodology 364
11.3.1 Overview 364
11.3.2 Coverage 364
11.3.3 Secondary Research 365
11.3.4 Forecasting Methodology 366
11.3.5 Primary Research – Key Opinion Leader Interviews 367
11.3.6 Expert Panel Validation 367
11.4 Physicians and Specialists Included in this Study 368
11.4.1 Dr. Alessandro Aprato 368
11.4.2 Dr. Fran Channa 368
11.4.3 Joseph Daniel FRCS MS (Orth) 368
11.4.4 Dr. Alejandro Gonzalez Della Valle 368
11.4.5 Dr. Moussa Hamadouche 368
11.4.6 Dr. Sheng-Li Huang and Xi-Jing He 368
11.4.7 Dr. Ayumi Kaneuji 368
11.4.8 Dr. Yuichi Mitani 368
11.4.9 Dr. Ning Lu 369
11.4.10 Dr. Deepak Saini 369
11.4.11 Dr. Lafayette Lage 369
11.4.12 Dr. Christoph Zilkens 369
11.5 About the Authors 370
11.5.1 Analysts 370
11.5.2 Global Head of Healthcare 371
11.6 About MediPoint 372
11.7 About GlobalData 372
11.8 Disclaimer 372
1.1 List of Tables

Table 1: Clinical Symptoms and Descriptions 37
Table 2: Advantages and Disadvantages of Hip Resurfacing 48
Table 3: Surgical Approaches Comparison 49
Table 4: Global Prevalence of Osteoarthritis in the Major EU Markets, millions, 2010–2019 54
Table 5: Direct and Indirect Costs of Arthritis 58
Table 6: Top Five Products Used in the UK, 2003–2011, by Popularity, by Component 63
Table 7: Bicontact Universal Hip System (B. Braun) 66
Table 8: Clinical Studies Bicontact Universal Hip System (B. Braun) 67
Table 9: SWOT Bicontact Universal Hip System 68
Table 10: Excia Hip Stem (B. Braun) 70
Table 11: Clinical Studies Excia Hip Stem (B. Braun) 71
Table 12: SWOT Excia Hip Stem 71
Table 13: Metha® Short Hip Stem (B. Braun) 73
Table 14: Clinical Studies Metha® Short Hip Stem (B. Braun) 74
Table 15: SWOT Metha® Short Hip Stem 74
Table 16: TRJ Cementless Hip Endoprosthesis System (B. Braun) 76
Table 17: SWOT TRJ Cementless Hip Endoprosthesis System 77
Table 18: Plasmacup SC Acetabular Cup (B. Braun) 78
Table 19: Balance Femoral Component (Biomet) 80
Table 20: Clinical Studies Balance Femoral Component (Biomet) 80
Table 21: SWOT Balance Femoral Component 81
Table 22: Bi-Metric Femoral Components (Biomet) 82
Table 23: Clinical Studies Bi-Metric Femoral Components (Biomet) 82
Table 24: SWOT Bi-Metric Femoral Components 83
Table 25: Bio-Moore II Hip System (Biomet) 84
Table 26: Clinical Studies Bio-Moore II Hip System (Biomet) 84
Table 27: SWOT Bio-Moore II Hip System 85
Table 28: Generation 4 Polished Hip System (Biomet) 86
Table 29: SWOT Generation 4 Polished Hip System 87
Table 30: Integral Porous Primary Hip System (Biomet) 88
Table 31: Clinical Studies Integral Porous Hip System (Biomet) 88
Table 32: SWOT Integral Porous Hip System Femoral Components 89
Table 33: Mallory Femoral Component (Biomet) 90
Table 34: Clinical Studies Mallory Femoral Component (Biomet) 91
Table 35: SWOT Mallory Femoral Component 91
Table 36: Progressive Total Hip System (Biomet) 92
Table 37: SWOT Progressive Total Hip System 93
Table 38: Rx 90 Smooth Primary Femoral Component (Biomet) 94
Table 39: SWOT Rx 90 Smooth Primary Femoral Component 94
Table 40: Stanmore Hip System (Biomet) 96
Table 41: Clinical Studies Stanmore Hip System (Biomet) 96
Table 42: SWOT Stanmore Hip System 97
Table 43: Taperloc and Balance Microplasty Hip Stems (Biomet) 98
Table 44: Clinical Studies Taperloc and Balance Microplasty Hip Stems (Biomet) 99
Table 45: SWOT Taperloc and Balance Microplasty Hip Stems 99
Table 46: Acetabular Systems (Biomet) 100
Table 47: Bencox Stems (Corentec Co. Ltd) 102
Table 48: Clinical Studies Bencox Stems (Corentec Co. Ltd) 103
Table 49: SWOT Bencox Stems 103
Table 50: Bencox Acetabular Systems (Corentec Co. Ltd.) 104
Table 51: MetaFix (Corin) 106
Table 52: SWOT MetaFix 107
Table 53: MiniHip (Corin) 108
Table 54: SWOT MiniHip 108
Table 55: MRP-Titan (Corin) 110
Table 56: SWOT MRP-Titan 110
Table 57: TaperFit (Corin) 112
Table 58: SWOT TaperFit 112
Table 59: Trinity Acetabular System (Corin) 114
Table 60: Cenator Acetabular Cup (Corin) 115
Table 61: Cementless Systems (DePuy Synthes) 117
Table 62: Clinical Studies Cementless Systems (DePuy Synthes) 117
Table 63: SWOT DePuy Synthes Cementless Systems 118
Table 64: Cemented Systems (DePuy Synthes) 119
Table 65: Clinical Studies Cemented Systems (DePuy Synthes) 119
Table 66: SWOT DePuy Synthes Cemented Systems 119
Table 67: DePuy Synthes Acetabular Systems (DePuy Synthes) 121
Table 68: AcuMatch Femoral Stems (Exactech) 123
Table 69: Clinical Studies AcuMatch Femoral Stems (Exactech) 123
Table 70: SWOT AcuMatch Femoral Stems 124
Table 71: Novation Femoral Stems (Exactech) 126
Table 72: Clinical Studies Novation Femoral Stems (Exactech) 127
Table 73: SWOT Novation Femoral Stems 127
Table 74: Exactech Acetabular Systems (Exactech) 128
Table 75: i-Hip Total Hip Implant (Iconacy Orthopedic Implants) 130
Table 76: SWOT i-Hip Total Hip Implant 130
Table 77: EcoFit Femoral Stem (Implantcast GMBH) 132
Table 78: Aida Short Femoral Stem (Implantcast GMBH) 133
Table 79: AJS Hip System (Implantcast GMBH) 135
Table 80: DiaLoc Hip Stem (Implantcast GMBH) 137
Table 81: LOAD SHIFT Hip Stem (Implantcast GMBH) 138
Table 82: Ceraco Hip Stem (Implantcast GMBH) 139
Table 83: IC Straight Stem Type I and Type II (Implantcast GMBH) 140
Table 84: Bicana Hip Stem (Implantcast GMBH) 141
Table 85: SWOT Implantcast GMBH Femoral Stems 142
Table 86: Implantcast GMBH Acetabular Cups (Implantcast GMBH) 144
Table 87: Aeon Hip System (JRI Orthopaedics) 145
Table 88: SWOT Aeon Hip System 146
Table 89: Furlong Hip System and Evolution System (JRI Orthopaedics) 147
Table 90: Clinical Studies Furlong Hip System (JRI Orthopaedics) 148
Table 91: SWOT Furlong Hip System and Evolution System 148
Table 92: Limacorporate Cementless Femoral Stems (Limacorporate SPA) 150
Table 93: SWOT Limacorporate Cementless Femoral Stems 150
Table 94: Cemented and Cementless Stems (Limacorporate SPA) 152
Table 95: SWOT Cemented and Cementless Stems (Limacorporate SPA) 152
Table 96: Limacorporate Acetabular Systems 153
Table 97: Cemented and Cementless Stems (Medacta) 155
Table 98: SWOT Medacta Stems 155
Table 99: Acetabular Cups and Femoral Heads (Medacta) 156
Table 100: Helicon Hip System (TGM Medical, wholly owned by Medtronic) 158
Table 101: SWOT Helicon Hip System 158
Table 102: Vektor Titan and Vektor CoCr (Peter Brehm GMBH) 160
Table 103: Clinical Studies Peter Brehm Stems (Peter Brehm GMBH) 160
Table 104: SWOT Peter Brehm Products 161
Table 105: Libra and Sagittal EVL (Serf Dedienne Santé) 163
Table 106: SWOT Libra and Sagittal EVL 163
Table 107: Acetabular Cups (Serf Dedienne Santé) 165
Table 108: Echelon and Synergy (Smith & Nephew) 167
Table 109: SWOT Echelon and Synergy 167
Table 110: Anthology Hip System (Smith & Nephew) 168
Table 111: SWOT Anthology Hip System 169
Table 112: CPCS and Spectron Hip System (Smith & Nephew) 170
Table 113: SWOT CPCS and Spectron Hip System 170
Table 114: Emperion and SMF Modular Stems (Smith & Nephew) 171
Table 115: SWOT Emperion and SMF Modular Stems 172
Table 116: Acetabular Cups (Smith & Nephew) 173
Table 117: ProClass Hip Stem (Stelkast) 174
Table 118: SWOT ProClass Hip Stem 174
Table 119: Progeny Hip Stem (Stelkast) 175
Table 120: SWOT Progeny Hip Stem 176
Table 121: Protract Hip Stem (Stelkast) 177
Table 122: SWOT Protract Hip Stem 177
Table 123: Provident Hip Stem (Stelkast) 178
Table 124: SWOT Provident Hip Stem 179
Table 125: Acetabular Cups (Stelkast) 181
Table 126: Cementless Stems (Stryker) 183
Table 127: SWOT Cementless Stems 183
Table 128: Cemented Stems (Stryker) 184
Table 129: SWOT Cemented Stems 185
Table 130: Acetabular Systems (Stryker) 187
Table 131: Diamond Total Hip Implant (Tianjin Zhengtian Medical Instruments) 188
Table 132: SWOT Diamond Total Hip Implant 189
Table 133: Linea Stem (Tornier N.V.) 191
Table 134: SWOT Linea Stem 192
Table 135: Meije Duo Stem (Tornier N.V.) 193
Table 136: SWOT Meije Duo Stem 194
Table 137: Oceane Stem (Tornier N.V.) 195
Table 138: SWOT Oceane Stem 196
Table 139: Tornier Femoral Heads (Tornier N.V.) 197
Table 140: Oceane Cup (Tornier N.V.) 198
Table 141: Tornier Dynacup (Tornier N.V.) 199
Table 142: Tornier Dual Mobility (Tornier N.V.) 200
Table 143: Perfecta Cementless and Cemented Stems (Wright Medical) 201
Table 144: SWOT Perfecta Cementless and Cemented Stems 202
Table 145: Cementless Femoral Stems (Wright Medical) 204
Table 146: SWOT Cementless Femoral Stems 205
Table 147: Cemented Femoral Stems (Wright Medical) 206
Table 148: SWOT Cemented and Cementless Femoral Stems (Wright Medical) 207
Table 149: Acetabular Systems (Wright Medical) 209
Table 150: UTF and UTF Reduced Stem (United Orthopedic Company) 211
Table 151: SWOT UTF and UTF Reduced Stem 211
Table 152: Hip U1 and U2 Stems (United Orthopedic Corporation) 212
Table 153: SWOT Acetabular Systems (United Orthopedic Corporation) 213
Table 154: Acetabular Systems (United Orthopedic Corporation) 214
Table 155: Press-Fit Stems (Zimmer Holdings Inc.) 216
Table 156: SWOT Press-Fit Stems 216
Table 157: Acetabular Systems (Zimmer Holdings Inc.) 218
Table 158: Exactech LPI Prime Hip System (Exactech) 232
Table 159: Regulatory Differences Between the US and EU 238
Table 160: Company Profile – B. Braun 250
Table 161: B. Braun Product Portfolio 251
Table 162: SWOT Analysis – B. Braun 251
Table 163: Company Profile – Biomet Orthopedics 252
Table 164: Biomet Product Portfolio 254
Table 165: SWOT Analysis – Biomet Orthopedics 256
Table 166: Company Profile – Corentec Co. Ltd. 257
Table 167: Corentec Product Portfolio 257
Table 168: SWOT Analysis – Corentec Co. Ltd. 258
Table 169: Company Profile – Corin Group 259
Table 170: Corin Group Product Portfolio 260
Table 171: SWOT Analysis – Corin Group 260
Table 172: Company Profile – DePuy Synthes International 262
Table 173: DePuy Synthes International Product Portfolio 262
Table 175: Company Profile – Exactech 266
Table 176: Exactech Product Portfolio 267
Table 177: SWOT Analysis – Exactech 268
Table 178: Company Profile – Iconacy Orthopedic Implants LLC 269
Table 179: Iconacy Orthopedic Implants LLC Product Portfolio 269
Table 180: SWOT Analysis – Iconacy Orthopedic Implants LLC 270
Table 181: Company Profile – Implantcast GMBH 271
Table 182: Implantcast GMBH Product Portfolio 272
Table 183: SWOT Analysis – Implantcast GMBH 273
Table 184: Company Profile – JRI Orthopaedics 274
Table 185: JRI Orthopaedics Product Portfolio 275
Table 186: SWOT Analysis – JRI Orthopaedics 276
Table 187: Company Profile – KYOCERA Medical Corporation 277
Table 188: KYOCERA Medical Corporation Product Portfolio 278
Table 189: SWOT Analysis – KYOCERA Medical Corporation 279
Table 190: Company Profile – Limacorporate S.P.A 280
Table 191: Limacorporate S.P.A Product Portfolio 281
Table 192: SWOT Analysis – Limacorporate S.P.A 282
Table 193: Company Profile – Medacta International 283
Table 194: Medacta International Product Portfolio 284
Table 195: SWOT Analysis – Medacta International 285
Table 196: Company Profile – Medtronic 286
Table 197: Medtronic Product Portfolio 287
Table 198: SWOT Analysis – Medtronic 287
Table 199: Company Profile – NovoSource Inc. 288
Table 200: NovoSource Inc. Product Portfolio 288
Table 201: SWOT Analysis – NovoSource Inc. 289
Table 202: Company Profile – Peter Brehm GMBH 289
Table 203: Peter Brehm GMBH Product Portfolio 290
Table 204: SWOT Analysis – Peter Brehm GMBH 290
Table 205: Company Profile – Serf Dedienne Santé 291
Table 206: Serf Dedienne Santé Product Portfolio 292
Table 207: SWOT Analysis – Serf Dedienne Santé 293
Table 208: Company Profile – Smith & Nephew 294
Table 209: Smith & Nephew Product Portfolio 295
Table 210: SWOT Analysis – Smith & Nephew 296
Table 211: Company Profile – Stelkast 297
Table 212: Stelkast Product Portfolio 298
Table 213: SWOT Analysis – Stelkast 298
Table 214: Company Profile – Stryker 300
Table 215: Stryker Product Portfolio 301
Table 216: SWOT Analysis – Stryker 302
Table 217: Company Profile – Tianjin Zhengtian Medical Instrument Co. Ltd. 303
Table 218: Tianjin Zhengtian Medical Instrument Co. Ltd. Product Portfolio 304
Table 219: SWOT Analysis – Tianjin Zhengtian Medical Instrument Co. Ltd. 304
Table 220: Company Profile – Tornier N.V. 306
Table 221: Tornier N.V. Product Portfolio 307
Table 222: SWOT Analysis – Tornier N.V. 308
Table 223: Company Profile – Wright Medical 309
Table 224: Wright Medical Product Portfolio 310
Table 225: SWOT Analysis – Wright Medical 312
Table 226: Company Profile – United Orthopedic Corporation 313
Table 227: United Orthopedic Corporation Product Portfolio 314
Table 228: SWOT Analysis – United Orthopedic Corporation 314
Table 229: Company Profile – Zimmer Holdings Inc. 316
Table 230: Zimmer Holdings Inc. Product Portfolio 317
Table 231: SWOT Analysis – Zimmer Holdings, Inc. 318
Table 232: Other Companies in the Global Hip Replacement Market 319
Table 233: EU Sales ($m) Forecast for THR, 2010–2019 332
Table 234: France Sales ($m) Forecast for THR, 2010–2019 337
Table 235: Germany Sales ($m) Forecast for THR, 2010–2019 339
Table 236: Italy Sales ($m) Forecast for THR, 2010–2019 340
Table 237: Spain Sales ($m) Forecast for THR, 2010–2019 342
Table 238: UK Sales ($m) Forecast for THR, 2010–2019 344
1.2 List of Figures

Figure 1: Anatomy of the Hip 33
Figure 2: Treatment Paradigm for Hip Osteoarthritis 40
Figure 3: Treatment Paradigm for Hip Fractures 41
Figure 4: Hip Arthrodesis 43
Figure 5: Partial Hip Arthroplasty and Total Hip Arthroplasty 47
Figure 6: Surgical Approach Used by Orthopedic Surgeons Globally 51
Figure 7: Population with Osteoarthritis in the EU, 2010–2019 58
Figure 8: EU Costs Related to Total Hip Replacement Procedure 61
Figure 9: Global Market Share for Reconstructive Products, 2012 63
Figure 10: Cementless, Cemented, Hybrid Product Usage by Orthopedic Surgeons, by Country 65
Figure 11: Bicontact Universal Hip System (B. Braun) 66
Figure 12: Excia Hip Stem (B. Braun) 70
Figure 13: Metha® Short Hip Stem (B. Braun) 73
Figure 14: TRJ Cementless Hip Endoprosthesis System (B. Braun) 76
Figure 15: Plasmacup SC Acetabular Cup (B. Braun) 79
Figure 16: Balance Femoral Component (Biomet) 80
Figure 17: Bi-Metric Femoral Components (Biomet) 82
Figure 18: Bio-Moore II Hip System (Biomet) 84
Figure 19: Generation 4 Polished Hip System (Biomet) 87
Figure 20: Integral Porous Primary Hip System (Biomet) 88
Figure 21: Mallory Femoral Component (Biomet) 91
Figure 22: Progressive Total Hip System (Biomet) 93
Figure 23: Rx 90 Smooth Primary Femoral Component (Biomet) 94
Figure 24: Stanmore Hip System (Biomet) 96
Figure 25: Taperloc and Balance Microplasty Hip Stems (Biomet) 98
Figure 26: Bencox Stems (Corentec Co. Ltd) 102
Figure 27: Bencox Acetabular Systems (Corentec Co. Ltd.) 105
Figure 28: MetaFix (Corin) 106
Figure 29: MiniHip (Corin) 108
Figure 30: MRP-Titan (Corin) 110
Figure 31: TaperFit (Corin) 112
Figure 32: Trinity Acetabular System (Corin) 114
Figure 33: Cenator Acetabular Cup (Corin) 116
Figure 34: Cementless Systems (DePuy Synthes) 117
Figure 35: Cemented Systems (DePuy Synthes) 119
Figure 36: DePuy Acetabular Systems (DePuy Synthes) 121
Figure 37: AcuMatch Femoral Stems (Exactech) 123
Figure 38: Novation Femoral Stems (Exactech) 126
Figure 39: i-Hip Total Hip Implant (Iconacy Orthopedic Implants) 130
Figure 40: EcoFit Femoral Stem (Implantcast GMBH) 132
Figure 41: Aida Short Femoral Stem (Implantcast GMBH) 134
Figure 42: AJS Hip System (Implantcast GMBH) 135
Figure 43: DiaLoc Hip Stem (Implantcast GMBH) 137
Figure 44: LOAD SHIFT Hip Stem (Implantcast GMBH) 139
Figure 45: Ceraco Hip Stem (Implantcast GMBH) 140
Figure 46: IC Straight Stem Type I and Type II (Implantcast GMBH) 141
Figure 47: Bicana Hip Stem (Implantcast GMBH) 142
Figure 48: Implantcast GMBH Acetabular Cups (Implantcast GMBH) 144
Figure 49: Aeon Hip System (JRI Orthopaedics) 146
Figure 50: Furlong Hip System and Evolution System (JRI Orthopaedics) 148
Figure 51: Cemented and Cementless Stems (Limacorporate SPA) 152
Figure 52: Cemented and Cementless Stems (Medacta) 155
Figure 53: Helicon Hip System (TGM Medical wholly owned by Medtronic) 158
Figure 54: Vektor-Titan and Vektor-CoCr (Peter Brehm GMBH) 160
Figure 55: Libra and Sagitta EVL (Serf Dedienne Santé) 163
Figure 56: Acetabular Cups (Serf Dedienne Santé) 165
Figure 57: Echelon and Synergy (Smith & Nephew) 167
Figure 58: Anthology Hip System (Smith & Nephew) 169
Figure 59: CPCS and Spectron Hip System (Smith & Nephew) 170
Figure 60: Emperion and SMF Modular Stems (Smith & Nephew) 172
Figure 61: Acetabular Cups (Smith & Nephew) 173
Figure 62: ProClass Hip Stem (Stelkast) 174
Figure 63: Progeny Hip Stem (Stelkast) 176
Figure 64: Protract Hip Stem (Stelkast) 177
Figure 65: Provident Hip Stem (Stelkast) 179
Figure 66: Acetabular Systems (Stelkast) 181
Figure 67: Cementless Stems (Stryker) 183
Figure 68: Cemented Stems (Stryker) 185
Figure 69: Acetabular Systems (Stryker) 187
Figure 70: Diamond Total Hip Implant (Tianjin Zhengtian Medical Instruments) 189
Figure 71: Linea Stem (Tornier N.V.) 191
Figure 72: Meije Duo Stem (Tornier N.V.) 193
Figure 73: Oceane Stem (Tornier N.V.) 195
Figure 74: Tornier Femoral Heads (Tornier N.V.) 197
Figure 75: Oceane Cup (Tornier N.V.) 198
Figure 76: Tornier Dynacup (Tornier N.V.) 200
Figure 77: Tornier Dual Mobility (Tornier N.V.) 201
Figure 78: Perfecta Cementless and Cemented Stems (Wright Medical) 202
Figure 79: Cementless Femoral Stems (Wright Medical) 204
Figure 80: Profemur Gladiator (Wright Medical) 207
Figure 81: Acetabular Systems (Wright Medical) 209
Figure 82: UTF and UTF Reduced Stem (United Orthopedic Corporation) 211
Figure 83: Hip U1 and U2 Stems (United Orthopedic Corporation) 213
Figure 84: Acetabular Systems (United Orthopedic Corporation) 215
Figure 85: Press-Fit Stems (Zimmer Holdings Inc.) 216
Figure 86: Acetabular Systems (Zimmer Holdings Inc.) 218
Figure 87: Europe Primary Hip Arthroplasty Procedure Volumes (2010–2019) 237
Figure 88: EU Sales ($m) Forecast for THR, 2010–2019 334
Figure 89: THR Revenue by Major Market, 2012 and 2019 335
Figure 90: THR Revision Surgery Revenue by Major Market, 2010 and 2019 336
Figure 91: France Sales ($m) Forecast for THR, 2010–2019 339
Figure 92: Germany Sales ($m) Forecast for THR, 2010–2019 340
Figure 93: Italy Sales ($m) Forecast for THR, 2010–2019 342
Figure 94: Spain Sales ($m) Forecast for THR, 2010–2019 343
Figure 95: UK Sales ($m) Forecast for THR, 2010–2019 345

Companies Mentioned

B. Braun
Biomet Orthopedics
Corentec Co. Ltd.
Corin
DePuy Synthes International
Exactech
Iconacy Orthopedic Implants LLC
Implantcast GMBH
JRI Orthopaedics
Kyocera
Limacorporate S.P.A
Medacta
Medtronic
NovoSource Inc.
Peter Brehm GMBH
Serf Dedienne S

Read the full report:

MediPoint: Total Hip Replacement - EU Analysis and Market Forecasts

http://www.reportbuyer.com/pharma_healthcare/treatments/orthopaedic/medipoint_total_hip_replacement_eu_analysis_market_forecasts.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Orthopedic

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: http://www.reportbuyer.com/


Contact

  • Sarah Smith
    Research Advisor at Reportbuyer.com
    +44 208 816 85 48
    Email